MyFinsight
Home
Blog
About
Maturities of marketable
securities
$54,500K
(-14.39%↓ Y/Y)
Exercise of common stock
options
$979K
(16216.67%↑ Y/Y)
Net cash provided by
(used in) investing...
$21,469K
(113.06%↑ Y/Y)
Net cash provided by
financing activities
$749K
(-99.63%↓ Y/Y)
Canceled cashflow
$33,031K
Canceled cashflow
$230K
Net increase in
cash, cash...
-$2K
(-100.06%↓ Y/Y)
Canceled cashflow
$22,218K
Stock-based compensation
expense
$6,842K
(38.67%↑ Y/Y)
Accrued expenses and
other current...
$2,704K
(222.85%↑ Y/Y)
Non-cash operating lease
expense
$492K
(-49.85%↓ Y/Y)
Depreciation expense
$155K
(-49.35%↓ Y/Y)
Purchases of marketable
securities
$33,031K
(-85.51%↓ Y/Y)
Payment of deferred
offering costs
$230K
Net cash used in
operating activities
-$22,220K
(35.48%↑ Y/Y)
Canceled cashflow
$10,193K
Net loss
-$29,886K
(13.50%↑ Y/Y)
Accounts payable
-$1,532K
(-463.24%↓ Y/Y)
Operating lease
liabilities
-$544K
(48.48%↑ Y/Y)
Prepaid expenses and
other current assets
$294K
(-59.17%↓ Y/Y)
Amortization of discount on
marketable securities
$157K
(-91.57%↓ Y/Y)
Back
Back
Cash Flow
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)
source: myfinsight.com